Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection

J Infect Dis. 2003 Apr 15;187(8):1264-71. doi: 10.1086/374561. Epub 2003 Apr 2.

Abstract

Cytotoxic T lymphocyte antigen-4 (CTLA4) suppresses cytotoxic T lymphocyte activity. We examined the associations of CTLA4 single-nucleotide polymorphisms (SNPs) at promoter site -318 and exon-1 site 49 with clearance of hepatitis C virus (HCV) after treatment with combination interferon-alpha plus ribavirin (IFN-alpha+R) therapy in 79 white sustained responders (SRs) and 79 nonresponders (NRs). SRs had higher frequencies of 49G, alone (odds ratio [OR], 2.3; P=.042) and tightly linked with -318C in a haplotype (OR, 2.4; P=.030). Homozygosity for the -318C-49G haplotype was even more frequent among SRs (OR, 5.2; P=.049). Comparably strong associations persisted after multivariable analysis. Relationships were not seen with non-1 genotype viruses (OR, 0.93-1.25; P>.25). Virus load also declined more rapidly in carriers of both 49G (P=.0095) and the -318C-49G haplotype. CTLA4 49G in exon 1 alone and in a haplotype with -318C promoter is associated with sustained IFNalpha+R response in white patients with HCV genotype 1 infection.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abatacept
  • Adult
  • Antigens, CD
  • Antigens, Differentiation / genetics*
  • Antigens, Differentiation / immunology*
  • Antiviral Agents / therapeutic use*
  • CTLA-4 Antigen
  • Female
  • Genetic Linkage
  • Hepacivirus / immunology*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics*
  • Hepatitis C, Chronic / immunology
  • Humans
  • Immunoconjugates*
  • Interferon-alpha / therapeutic use*
  • Male
  • Pharmacogenetics
  • Polymorphism, Single Nucleotide / genetics*
  • Ribavirin / therapeutic use*
  • Time Factors

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • Antiviral Agents
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Immunoconjugates
  • Interferon-alpha
  • Ribavirin
  • Abatacept